Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
MP4OX is a novel oxygen therapeutic agent specifically developed to perfuse and oxygenate
tissue at risk for ischemia and hypoxia. MP4OX is a pegylated hemoglobin-based colloid and
and as a result of its molecular size and unique oxygen dissociation characteristics, targets
oxygen delivery to ischemic tissues by selectively off-loading oxygen in tissues predisposed
to low oxygen tension. Sangart is currently evaluating MP4OX to reduce organ dysfunction and
failure in trauma patients with lactic acidosis due to severe hemorrhagic shock.